Evidence map›Paper›PMID 41085623›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Characterization of Human Leukocyte Antigen (HLA) Proteins with Integrated Immunopeptidomics and Proteomics Approach.

Rui Chen, Jianjun Li

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rui ChenHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada. Rui.Chen@nrc-cnrc.gc.ca.
Jianjun LiHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Killing of cancer cells by cytotoxic Tcells requires efficient presentation of tumor antigens by human leukocyte antigen (HLA) molecules and patient-specific HLA genotypes also influence response to immune checkpoint inhibitors. Genotyping for a specific HLA allele can be used as biomarker to predict the immunotherapy outcome of a patient. Traditionally, HLA genotyping is achieved by sequencing the genome or transcriptome extracted from whole cells. Unfortunately, this approach does not reflect the actual abundance of each expressed HLA allele that presents antigen on the cell surface or provide any information on the post-translational modification of HLA proteins. To tackle this problem, we present an integrated immunopeptidomics and proteomics approach to comprehensively characterize the HLA proteins. HLA proteins are captured from traditional immunopeptidomics analysis and subjected to digestion, glycopeptides enrichment, and mass spectrometric analysis. Database with the mass spectrometric data will provide the relative expression level of each HLA allele and its pattern of glycosylation, which improves the understanding of antigen presentation.

Indexed as

HLA AntigensPeptidesProteomicsAllelesAntigen PresentationGlycosylationHumansMass SpectrometryProtein Processing, Post-TranslationalHLA AntigensPeptidesGlycosylationHuman leucocyte antigenLC-MS/MSMajor histocompatibility complex

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.